Exact Sciences (EXAS) AI Stock Analysis

• Market Cap: $7.90B
• Dividend Yield: N/A
• Average Volume (3M): 3.06M
• Price to Earnings (P/E): ―
• Beta (1Y): 0.62
• Revenue Growth: 12.56%
• EPS Growth: -464.28%
• Country: US
• Employees: 6,900
• Sector: Healthcare
• Sector Strength: 43
• Industry: Medical - Diagnostics & Research
• EPS (TTM): -0.01
• Shares Outstanding: 189,319,100
• 10 Day Avg. Volume: 5,031,606
• 30 Day Avg. Volume: 3,057,761
• PEG Ratio: N/A
• Price to Book (P/B): N/A
• Price to Sales (P/S): N/A
• P/FCF Ratio: N/A
• Enterprise Value/Market Cap: 1.48
• Enterprise Value/Revenue: 3.99
• Enterprise Value/Gross Profit: 5.84
• Enterprise Value/Ebitda: -14.31
• 1Y Price Target: $61.44
• Price Target Upside: 36.56% Upside
• Rating Consensus: Strong Buy
• Number of Analyst Covering: 19

• Rating: 48 Neutral
• Price Target: $44.00 ▼(-2.20% Downside)

The overall stock score is primarily impacted by financial performance challenges, including profitability and cash flow issues. While the earnings call and corporate events provide positive strategic insights, the lack of technical analysis data and poor valuation metrics weigh heavily on the score.

Positive Factors

Financial Performance

The company generated total revenue of $811.1 million, with Screening revenue increasing 18% and Precision Oncology revenue up 9%.

Product Development

Cologuard Plus offers performance improvements over the first-generation Cologuard, with higher sensitivity and specificity, and a significant reduction in false positives.

Strategic Partnerships

Exact Sciences announced exclusive rights in the U.S. to Freenome’s CRC screening tests, with potential additional payments based on achieving regulatory milestones.

Negative Factors

Clinical Trial Results

The disappointing BLUE-C liquid biopsy trial results landed below the NCD requirement of 74% sensitivity, yielding a test that is very unlikely to have commercial potential.

Market Competition

EXAS is unlikely to launch Freenome's assay until it receives FDA approval, placing it at least 2 years behind competitor GH Shield.

Product Performance

Exact Sciences' own blood colorectal cancer test did not meet expectations in the pivotal trial.

Exact Sciences Business Overview & Revenue Model

Company Description

Exact Sciences Corporation is a molecular diagnostics company based in Madison, Wisconsin, primarily focused on the early detection and prevention of cancer. The company operates in the healthcare sector, specializing in non-invasive screening tests for colorectal and other cancers. Its flagship product, Cologuard, is a stool-based DNA test designed to detect colorectal cancer and precursors to the disease, while the company is also involved in developing tests for other types of cancers, enhancing its portfolio of oncology-focused diagnostic solutions.

How the Company Makes Money

Exact Sciences generates revenue primarily through the sale of its diagnostic tests, particularly Cologuard, which is reimbursed by various healthcare payers, including Medicare and private insurance providers. The company also earns revenue from laboratory services and partnerships with other healthcare organizations to expand its test offerings and reach. Significant partnerships, such as collaborations with pharmaceutical companies and healthcare systems, help enhance its market presence and contribute to its earnings. Additionally, Exact Sciences invests in research and development to innovate and broaden its test portfolio, aiming to capture more market share in the oncology diagnostics space.

Exact Sciences Financial Statement Overview

Summary

Exact Sciences shows strong revenue growth and a solid gross profit margin, but faces significant profitability challenges with negative net and EBIT margins. The balance sheet is stable with moderate leverage, yet profitability improvements are needed. Cash flow metrics display positive momentum, though converting earnings into free cash flow remains an area for improvement.

Income Statement

Exact Sciences shows a consistent revenue growth trend, with a TTM (Trailing-Twelve-Months) revenue increase of 2.5% compared to the previous year. However, the company is currently experiencing significant profitability challenges, with a negative net profit margin of -36.1% and a negative EBIT margin of -36.5%. The gross profit margin is relatively strong at 68.2%, indicating good management of direct costs. Overall, the income statement reflects growth potential but significant profitability issues.

Balance Sheet

The balance sheet of Exact Sciences indicates moderate financial health. The debt-to-equity ratio is 1.05, suggesting a balanced approach to leverage. The equity ratio is 41.9%, showing a stable foundation of equity financing. However, the return on equity is negative due to persistent net losses, highlighting the need for improved profitability to enhance shareholder value.

Cash Flow

Exact Sciences has shown improvement in cash flow metrics, with a TTM free cash flow growth rate of 160.3%. The operating cash flow to net income ratio is 0.32, reflecting some ability to convert earnings into cash. However, the free cash flow to net income ratio is negative, indicating challenges in generating free cash flow from operations. While there is positive cash flow momentum, profitability issues remain a concern.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	2.94B	2.76B	2.50B	2.08B	1.77B	1.49B
Gross Profit	2.00B	1.92B	1.85B	1.51B	1.31B	1.14B
EBITDA	-818.55M	-788.73M	41.88M	-386.74M	-617.73M	-632.86M
Net Income	-1.01B	-1.03B	-204.15M	-623.51M	-595.63M	-848.53M
Balance Sheet
Total Assets	5.80B	5.93B	6.47B	6.23B	6.68B	4.93B
Cash, Cash Equivalents and Short-Term Investments	858.43M	1.04B	777.64M	632.06M	1.03B	1.84B
Total Debt	2.54B	2.75B	2.55B	2.45B	2.36B	1.46B
Total Liabilities	3.33B	3.53B	3.33B	3.18B	3.30B	2.10B
Stockholders Equity	2.47B	2.40B	3.15B	3.04B	3.39B	2.82B
Cash Flow
Free Cash Flow	169.62M	74.55M	31.93M	-438.02M	-238.00M	72.13M
Operating Cash Flow	305.61M	210.54M	156.12M	-223.56M	-102.24M	136.48M
Investing Cash Flow	66.87M	-442.15M	49.68M	74.07M	-1.08B	-702.04M
Financing Cash Flow	-250.41M	231.87M	159.77M	76.48M	8.47M	1.88B

Exact Sciences Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 44.99
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For EXAS, the sentiment is Negative. The current price of 44.99 is below the 20-day moving average (MA) of 46.46, below the 50-day MA of 50.69, and below the 200-day MA of 52.46, indicating a bearish trend. The MACD of -2.25 indicates Positive momentum. The RSI at 42.18 is Neutral, neither overbought nor oversold. The STOCH value of 52.48 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for EXAS.

Exact Sciences Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
QGEN	72 Outperform	$10.60B	28.66	10.81%	2.56%	5.15%	412.41%
ILMN	70 Neutral	$14.97B	12.81	68.11%	―	-3.32%	―
NTRA	67 Neutral	$21.93B	―	-24.32%	―	44.38%	22.87%
Sector *	51 Neutral	$7.44B	-0.20	-46.00%	2.27%	22.80%	-2.27%
GH	49 Neutral	$7.53B	―	-4584.47%	―	28.74%	18.25%
EXAS	48 Neutral	$7.90B	―	-35.51%	―	12.56%	-464.28%
NEO	44 Neutral	$785.41M	―	-11.76%	―	9.70%	-30.94%

Exact Sciences Corporate Events

Exact Sciences Announces Collaboration with Freenome Holdings

On August 6, 2025, Exact Sciences announced a collaboration with Freenome Holdings to develop blood-based colorectal cancer screening products. The company reported record second-quarter revenue of $811 million, a 16% increase from the previous year, and raised its full-year revenue and adjusted EBITDA guidance. Key achievements included gaining Medicare coverage for its Oncodetect test and launching a multi-year productivity plan targeting $150 million in savings by 2026.

The most recent analyst rating on (EXAS) stock is a Buy with a $65.00 price target. To see the full list of analyst forecasts on Exact Sciences stock, see the EXAS Stock Forecast page.

Exact Sciences Shareholders Approve 2025 Incentive Plan

On June 12, 2025, Exact Sciences Corporation held its annual meeting where shareholders approved the 2025 Omnibus Long-Term Incentive Plan and an amendment to the 2010 Employee Stock Purchase Plan. Additionally, the shareholders elected seven directors, ratified the appointment of PricewaterhouseCoopers as the company’s independent auditor for 2025, and approved executive compensation. However, a proposal for a director election resignation governance policy was not approved.

The most recent analyst rating on (EXAS) stock is a Buy with a $65.00 price target. To see the full list of analyst forecasts on Exact Sciences stock, see the EXAS Stock Forecast page.